Entrada Therapeutics Inc TRDA.OQ TRDA.O is expected to show a fall in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025
The Boston Massachusetts-based company is expected to report a 82.8% decrease in revenue to $10.171 million from $59.12 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Entrada Therapeutics Inc is for a loss of 79 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Entrada Therapeutics Inc is $23.00, above its last closing price of $9.23.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.67 | -0.67 | 0.03 | Beat | 104.5 |
Sep. 30 2024 | -0.71 | -0.73 | -0.35 | Beat | 51.9 |
Jun. 30 2024 | 0.14 | 0.15 | 1.55 | Beat | 969 |
Mar. 31 2024 | -0.61 | -0.59 | 0.68 | Beat | 214.5 |
Dec. 31 2023 | 0.12 | -0.17 | -0.29 | Missed | -72.6 |
Sep. 30 2023 | -0.76 | -0.74 | 1.02 | Beat | 238.6 |
Jun. 30 2023 | -0.68 | -0.69 | -0.78 | Missed | -13 |
Mar. 31 2023 | 0.90 | 0.97 | -0.21 | Missed | -121.7 |
This summary was machine generated May 5 at 13:14 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。